戻る Agenda
Session 4 Track 2: Optimizing Oligonucleotide Therapeutics: Translating PK/PD and Tissue Half-Life into Smarter Dose Selection and Risk Assessment
Session Chair(s)
Tod Harper, PHD
Scientific Associate Director, Amgen, United States
Representative Invited
FDA, United States
Session 4 Track 2: Optimizing Oligonucleotide Therapeutics: Translating PK/PD and Tissue Half-Life into Smarter Dose Selection and Risk Assessment
Speaker(s)
Representative Invited
Senior Director, Oligo ADME Strategy, GlaxoSmithKline, United Kingdom
Translational PK/PD Modeling Considerations
Representative Invited
SVP of Translational DMPK and Clinical Pharmacology, Stoke Therapeutics, United States
Role of Tissue Half Life in Designing Clinical Studies
Tod Harper, PHD
Scientific Associate Director, Amgen, United States
Nonclinical Dose Selection, Safety Margins, and Translational Strategies for Oligonucleotide-based Therapeutics: Results from an IQ DruSafe ONT Working Group Cross-Industry Survey